ValuEngine Lowers Regenxbio (RGNX) to Hold
ValuEngine downgraded shares of Regenxbio (NASDAQ:RGNX) from a buy rating to a hold rating in a report published on Wednesday morning.
Several other brokerages have also recently weighed in on RGNX. Raymond James lifted their price target on shares of Regenxbio from $76.00 to $96.00 and gave the stock an outperform rating in a research note on Friday, September 7th. TheStreet upgraded shares of Regenxbio from a d+ rating to a c rating in a research note on Monday, September 17th. BidaskClub upgraded shares of Regenxbio from a hold rating to a buy rating in a research note on Saturday, November 3rd. Zacks Investment Research upgraded shares of Regenxbio from a hold rating to a buy rating and set a $78.00 price target on the stock in a research note on Wednesday, November 7th. Finally, Chardan Capital dropped their price target on shares of Regenxbio from $130.00 to $127.50 and set a buy rating on the stock in a research note on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $77.81.
Shares of Regenxbio stock opened at $52.44 on Wednesday. The firm has a market cap of $2.01 billion, a PE ratio of 27.00, a price-to-earnings-growth ratio of 8.29 and a beta of -0.53. Regenxbio has a 1-year low of $23.25 and a 1-year high of $85.10.
In related news, CFO Vittal Vasista sold 73,418 shares of Regenxbio stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $70.20, for a total transaction of $5,153,943.60. Following the transaction, the chief financial officer now owns 147,242 shares in the company, valued at approximately $10,336,388.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kenneth T. Mills sold 7,510 shares of Regenxbio stock in a transaction on Monday, September 17th. The shares were sold at an average price of $74.91, for a total transaction of $562,574.10. Following the transaction, the insider now owns 339,505 shares in the company, valued at approximately $25,432,319.55. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 448,954 shares of company stock worth $28,902,916. 16.90% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP lifted its stake in shares of Regenxbio by 74.0% during the 3rd quarter. Marshall Wace LLP now owns 356,786 shares of the biotechnology company’s stock valued at $26,937,000 after buying an additional 151,737 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Regenxbio by 51.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after buying an additional 947,671 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Regenxbio by 30.9% during the 3rd quarter. Legal & General Group Plc now owns 69,908 shares of the biotechnology company’s stock valued at $5,281,000 after buying an additional 16,522 shares in the last quarter. Kepos Capital LP purchased a new position in shares of Regenxbio during the 3rd quarter valued at $5,155,000. Finally, Teachers Advisors LLC lifted its stake in shares of Regenxbio by 6.5% during the 3rd quarter. Teachers Advisors LLC now owns 221,979 shares of the biotechnology company’s stock valued at $16,759,000 after buying an additional 13,537 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Why do earnings reports matter?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.